<DOC>
	<DOCNO>NCT02978313</DOCNO>
	<brief_summary>Investigating efficacy Cetuximab Monotherapy versus Continuation induction treatment chemotherapy + Cetuximab inoperable irresectable non-progressive metastatic colorectal cancer first line induction treatment 24 week mFOLFOX6/FOLFIRI Cetuximab treatment . Reinduction treatment do case progression .</brief_summary>
	<brief_title>Cetuximab Monotherapy Maintenance Treatment mCRC</brief_title>
	<detailed_description>Investigating efficacy Cetuximab Monotherapy versus Continuation induction treatment chemotherapy + Cetuximab inoperable irresectable non-progressive metastatic colorectal cancer first line induction treatment 24 week mFOLFOX6/FOLFIRI Cetuximab treatment . Reinduction treatment do case progression . This treatment continue progression severe toxicity .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Histological proof colorectal cancer ( case single metastasis , histological cytological proof lesion obtain ) ; Distant metastasis ( patient local recurrence eligible ) ; Unidimensionally measurable disease ( &gt; 1 cm spiral CT scan &gt; 2 cm chest Xray ; liver ultrasound allow ) . Serum CEA may use parameter disease evaluation ; In case previous radiotherapy , least one measurable lesion locate outside irradiated field ; Ongoing plan first line treatment 6 cycle mFOLFOX6/FOLFIRI plus Cetuximab . At randomisation : WHO performance status 01 ( Karnofsky PS &gt; 70 % ) ; Laboratory value obtain ≤ 2 week prior randomisation : adequate bone marrow function ( Hb &gt; 6.0 mmol/L , absolute neutrophil count &gt; 1.5 x 109/L , platelet &gt; 100 x 109/L ) , renal function ( serum creatinine ≤ 1.5x ULN creatinine clearance , Cockroft formula , &gt; 30 ml/min ) , liver function ( serum bilirubin ≤ 2 x ULN , serum transaminase ≤ 3 x ULN without presence liver metastases ≤ 5x ULN presence liver metastasis ) ; Negative pregnancy test woman childbearing potential ; Expected adequacy followup ; Institutional Review Board approval ; Written inform consent Exclusion criterion ; History clinical signs/symptoms CNS metastasis ; History second malignancy ≤ 5 year exception adequately treat carcinoma cervix basal/squamous cell carcinoma skin . Prior adjuvant treatment stage II/III colorectal cancer end within 6 month start induction treatment ; Any prior adjuvant treatment resection distant metastasis ; Previous systemic treatment advance disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>